GSK reported Q1 core operating profit of £2.65 bn, up 10% YoY and beating consensus of £2.46 bn.
Legal settlement provisions contributed roughly half of the profit outperformance, while total sales rose 5% to £7.6 bn, matching forecasts.
Specialty Medicines grew 14% to £3.2 bn, led by HIV (£1.8 bn, +10%) and a 28% rise in respiratory‑immunology‑oncology sales.
GSK reaffirmed 2026 guidance (turnover +3‑5%, profit +7‑9%), announced a 15p dividend and a strategy update from CEO Emma Walmsley.